<DOC>
	<DOCNO>NCT00002294</DOCNO>
	<brief_summary>To compare safety effectiveness fluconazole placebo maintenance treatment prevent relapse cryptococcal meningitis patient AIDS .</brief_summary>
	<brief_title>A Study Fluconazole Treatment Cryptococcal Meningitis Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiviral therapy ( e.g. , zidovudine ) . Prophylaxis ( include aerosolize pentamidine ) Pneumocystis carinii pneumonia ( PCP ) . Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Patients must orient person , place , time able give write informed consent . Patients must acute episode cryptococcal meningitis document recovery identification cryptococcus lumbar cerebrospinal fluid ( CSF ) culture within 4 month study entry . Adequate therapy consist 6 16 week treatment amphotericin B alone , amphotericin B + oral flucytosine , period combination follow amphotericin alone . Adequate regimen include : A minimum total amphotericin B dose 2 gram monotherapy . 6 week flucytosine 150 mg/kg/day ( level 20 100 mcg/ml demonstrate ) plus amphotericin B average daily dose least 0.3 mg/kg/day total dose 1 gram . After short period combination amphotericin/flucytosine therapy , additional Y gram amphotericin B monotherapy make therapy adequate Y = 2 gm ( X week combination therapy / 3 week ) . For example , patient receive 3 week combination follow amphotericin alone would need additional 2 gm 3 weeks/3 week = 1 gm amphotericin B . Patients need receive amphotericin B time randomization must begin study maintenance therapy within 3 week cessation primary amphotericin B therapy . Prior Medication : Allowed : Antiviral therapy ( e.g. , zidovudine ( AZT ) ) . Prophylaxis ( include aerosolize pentamidine ) Pneumocystis carinii pneumonia ( PCP ) . Exclusion Criteria Coexisting Condition : Patients follow exclude : Clinical evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole , azoles , amphotericin B . Moderate severe liver disease . Concurrent Medication : Excluded : Intrathecal amphotericin B. Coumarintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Concurrent Treatment : Excluded : Lymphocyte replacement . Patients follow exclude : Clinical evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole , azoles , amphotericin B . Moderate severe liver disease define specific lab value . Inability take oral medication reliably . Prior Medication : Excluded : Intrathecal amphotericin B. Coumarintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Prior Treatment : Excluded : Lymphocyte replacement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1989</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>